On February 1, 2018, Andrew Lees spoke at the Keystone meeting, Emerging Technologies in Vaccine Discovery and Development, held in Banff, Alberta, Canada. He chaired the session, “New Tools in…
“The Medicine Maker Power List hails one hundred of the best and brightest individuals involved in drug development. It’s fair to say that the pharmaceutical industry is not always looked upon favourably by the public,…
Fina Biosolutions is pleased to offer EcoCRMTM, economical CRM197 from E. coli, to the research and vaccine manufacturing community. CRM197, a genetically detoxified diphtheria toxin, is widely used as a…
Dr. Andrew Lees, founder and Chief Scientific Officer of Fina Biosolutions, has been named to The Power List 2016 – the Top 100 most influential people in the world of…
This technical paper by presents an overview of the development and applications of antibody dextran conjugates. Fina Biosolutions provides anti-IgD and anti-IgM dextrans (mouse and human) as well as other…
An esteemed research scientist and world-recognized leader in vaccine development, Andrew Lees founded Fina BioSolutions, a company committed to eliminating vaccine-preventable deaths of infants and children in emerging-market countries. With…
SNNLive spoke with Andrew Lees, Ph.D., Scientific Director of Fina Biosolutions LLC at the BioMaryland Booth at BIO International 2015 in Philadelphia, PA.
Dr. Lees will discuss the challenges of developing and manufacturing affordable conjugate vaccines. He will review how efficient conjugation chemistry and affordable carrier protein can help reduce manufacturing costs.
Comparison with Other Commercially Available Amino Dextrans The performance of AmDex in any application depends on its homogeneity and purity. The low percent dextran found in competitor AmDex means that…